NEW YORK — Cosmetic drugmaker Allergan Inc. said Friday its eyelash treatment Latisse received Food and Drug Administration approval.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
The drug treats the condition hypotrichosis of the eyelashes and is applied once-daily to increase thickness and fullness, the company said. The treatment has full results within 16 weeks, it said.
"Latisse fulfills a significant and previously unmet need in the medical aesthetic marketplace with a product approved by the FDA that increases the growth of eyelashes, making them longer, thicker and darker," said Dr. Scott Whitcup, Allergan's executive vice president of research and development, in a statement.
The drug's active ingredient, bimatoprost, was first approved in 2001 as a treatment to lower intraocular pressure in people with a type of glaucoma or hypertension within the eye.
Allergan expects to launch Latisse in the first quarter and forecasts peak annual sales exceeding $500 million.
Copyright 2008 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.